ADAPT (A Direct Aspiration First Pass Technique) 2.0 combines 0.088” intracranial access, asymmetric aspiration, and the continuous dual aspiration technique (CDAT) to provide fast and effective clot removal. Campbell, California-based Imperative Care’s Zoom Stroke System is the only mechanical thrombectomy system capable of performing a procedure using this approach, the company said in a news release.
Investigators shared findings at the Society of Vascular and Interventional Neurology (SVIN) 2025 Annual Meeting in Orlando.
ADAPT 2.0 represents the evolution of the original ADAPT technique, Imperative Care said. It initially studied this approach in 2014, demonstrating the clinical value of direct aspiration as a frontline treatment method. This next-generation version brings the 0.088” catheter closer to the clot. The aim is to improve clot ingestion through asymmetric aspiration and reduce the risk of losing the clot by applying continuous dual aspiration.
Imperative Care said it believes the approach offers greater control and consistency during thrombectomy procedures.
Data came from 124 consecutive ischemic stroke patients treated with ADAPT 2.0 using the Zoom Stroke System. Treatments took place between April 2025 and September 2025. Dr. Max Mokin of the University of South Florida presented findings.
Outcomes included a 97% rate of final modified thrombolysis in cerebral infarction (mTICI) ≥ 2b (120/124) and an 80% rate of final mTICI ≥ 2c (99/124). Median procedure time took 17 minutes, with a median of one pass per procedure. Mokin reported a 98% rate of full clot ingestion and capture in one or both Zoom PODs (111/113). The outer Zoom 88 POD captured clot in 35% of cases (40/113), which may have otherwise been lost.
“We are thrilled to see the procedural benefits of ADAPT 2.0 – a potential next frontier in stroke care – represented so clearly in the results of this study,” said Emir Deljkich, SVP of clinical affairs. “The combined power of 0.088” intracranial access, asymmetric aspiration, and CDAT using the Zoom Stroke System, allows physicians to not only streamline their procedures by using fewer devices, but gain greater control over the clot. This translates to faster and simpler procedures, as evidenced by a 17-minute median procedure time reported in this real-world dataset. Recent clinical data demonstrated that a faster puncture-to-reperfusion time led to a higher rate of functional independence – pointing to the critical importance of treatment time for stroke patients. We look forward to gathering additional prospective evidence to further validate the clinical performance of ADAPT 2.0 in stroke thrombectomy.”
